New research is giving the shingles shot a surprising second life in the health conversation, with fresh evidence pointing to a lower dementia risk in older adults. The big message is simple enough: the vaccine is still meant to prevent shingles, but the data keeps hinting at a bonus connection to brain health.
A study published in The Annals of Internal Medicine looked at electronic health records and Medicare claims from more than 509,926 U.S. adults age 66 and older living in skilled nursing facilities. Among those who received at least one dose of Shingrix, researchers found a 24% relative reduction in dementia risk over four years compared with people who did not get the vaccine.
That number has grabbed attention, but the details matter. The researchers were careful to say the findings show an association, not proof that the vaccine directly prevents dementia. Even so, the size of the dataset and the consistency of the results make this hard to ignore.
Neurologist Dr. Ajeet Sodhi said the result fits into a growing pattern rather than standing alone as some random one-off. In his view, this looks like the third or fourth study pointing in the same direction, which is why the signal is getting harder to dismiss.
“This is maybe the third or fourth study, and they all came to the same conclusion,” Sodhi said. “It seems that by giving patients the shingles vaccine called Shingrix, in the next couple of years, we see a clinically significant decline in the development of dementia.”
Researchers have floated a few explanations for why the link might exist. One idea is that preventing shingles also reduces the complications that can follow, including neurological and vascular problems that may affect cognition over time.
That matters because shingles is not just a rash. It is caused by the varicella-zoster virus, the same virus behind chickenpox, and it can sit quietly in the body for years before waking up again as a painful, blistering outbreak.
Once reactivated, shingles can hit hard. One of the most dreaded complications is post-herpetic neuralgia, a stubborn nerve pain that can linger long after the rash fades and make life miserable for older adults.
Sodhi also pointed to broader benefits tied to the vaccine, including possible cardiovascular and cerebrovascular gains. He noted that recent studies have suggested fewer heart attacks, strokes, and related events among vaccinated people, which could matter because vascular damage often overlaps with dementia risk.
“In addition to the study that we’re talking about today, there was a study published just this week that showed the shingles vaccine results in a clinically significant reduction in the incidence of both cardiovascular disease and cerebrovascular disease,” he said. “So that’s heart attacks and strokes.”
Still, the central point stays the same. The vaccine is not currently considered a treatment for dementia, and nobody should treat it like a cure or a shortcut for memory loss.
“It’s not at this time considered a treatment,” Sodhi noted. “This association is … very, very suggestive, but we can’t say one-to-one it proves that this treats dementia. And this finding, honestly, is kind of like icing on the cake.”
For now, the approved purpose of Shingrix remains straightforward: protect against shingles and its complications. The CDC recommends two doses for adults 50 and older, along with adults 19 and older who are or will be immunocompromised.
The study was funded by GSK, the maker of Shingrix, though the authors said the company had no role in the design, analysis, or publication of the research. That keeps the focus where it belongs, on the results and what they might mean for aging brains.
For anyone dealing with memory changes or a family history of dementia, the advice from specialists is to act early rather than wait. The pattern across these studies keeps circling back to the same idea: catching problems sooner gives doctors more room to help, and that window matters more than people often realize.
